A long-term monitoring study to evaluate the persistence of direct acting antiviral (DAA) treatment-resistant mutations or the durability of sustained virological response (SVR) in patients treated with DAA-containing regimens for chronic hepatitis C infection (CHC)
This observational long-term follow-up study will assess the persistence of direct acting
antiviral (DAA) resistant mutations and the durability of sustained virological response in
patients with chronic hepatitis C who have participated in a Roche DAA treatment protocol.
Up to 5 scheduled monitoring visits for blood sampling during an observational period of up
to 36 months.
adult patients, >/=18 years of age
chronic hepatitis C
participation in Roche DAA treatment protocol for CHC infection
DAA-associated resistant mutations persisting through to last evaluation in donor protocol , or partial viral response or viral load rebound while on RO5024048 treatment, or sustained virological response >/= 20 weeks after last dose of study medication in donor study
For patients participating in DAA resistance monitoring: Initiation of treatment after participation in the donor protocol for which there is evidence of cross-resistance to donor protocol DAA
For patients participating in DAA SVR durability: Treatment with any anti-HVC therapy since establishing SVR in the donor study